Intellicell™ Biosciences, Inc. is an emerging leader in regenerative medicine using adipose (fat) derived stromal vascular fraction containing adult stem cells. To date, the Company has developed proprietary technologies that allows for the efficient and reproducible separation of stromal vascular fraction (branded "IntelliCell™") containing adipose stem cells that can be performed in tissue processing centers and in doctor's offices. The Company is also engaged in clinical studies at major medical centers to obtain FDA approval for clinical indications for their IntelliCells.
IntelliCell BioSciences (OTCQB:SVFC) said Monday that it has inked an exclusive agreement with Millipore Corporation to supply and sell Millipore's guava flow cytometry platform, used for the manufacturing of stromal vascular fraction (SVF) containing adipose-derived adult stem cells.
The use of autologous adipose, or fat stem cells for a growing variety of indications is a new and exciting frontier in medicine. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells, the field has expanded rapidly.
Currently, numerous doctors are studying the use of these cells for aesthetics, the treatment of arthritis, and several orthopedic injuries such as knees, elbows, back, and shoulders, as well as more serious ailments like heart disease.
The collaboration between the two companies is expected to streamline the development of IntelliCell's tissue processing centres throughout the US, as it continues to expand amid increasing demand for the cells it sources from fatty tissue. The centres receive and employ the IntelliCell process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells to the physicians the same day.
The company has already established processing centers in Baton Rouge, New York City, Philadelphia, Dallas/Ft. Worth, Denver, Houston, New Orleans, Orlando, and West Palm Beach.
"This is a phenomenal step in the right direction for our company and we welcome the opportunity to work with Millipore," said IntelliCell chairman and CEO, Dr. Steven Victor.
"The exclusive agreement with Millipore to supply and sell their cutting-edge guava flow cytometer, combined with our proprietary process which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat."
"As the only company to use precise methods of counting cells and checking specimens for cell viability, dead cells, or debris, this is yet another milestone in our quest to become market leader in the area of separation of SVF, which greatly differentiates us from all other companies that manufacture these cells."
Shares of IntelliCell soared over 21%, to close at $3.95 on Monday.